

# Neurology

			Phase 1	Phase 2	Phase 3
<b>valbenazine*</b>	Sprinkle Formulation	VMAT2 Inhibitor			
<b>valbenazine*</b>	Dyskinetic Cerebral Palsy	VMAT2 Inhibitor			
<b>NBI-827104§</b>	Rare Pediatric Epilepsy: EE-CSWS	Ca <sub>v</sub> 3.1, 3.2, 3.3			
<b>NBI-921352##</b>	Rare Pediatric Epilepsy: SCN8A-DEE	Na <sub>v</sub> 1.6			
<b>NBI-1076986  </b>	Movement Disorders	M4 Antagonist			

# Neuroendocrinology

<b>crinecerfont†</b>	Congenital Adrenal Hyperplasia in Adults	CRF <sub>1</sub>			
<b>crinecerfont†</b>	Congenital Adrenal Hyperplasia in Children & Adolescents	CRF <sub>1</sub>			
<b>modified-release hydrocortisone</b>	Adrenal Insufficiency	GC Receptor			
<b>modified-release hydrocortisone</b>	Congenital Adrenal Hyperplasia	GC Receptor			

# Neuropsychiatry

<b>valbenazine*</b>	Adjunctive Treatment of Schizophrenia	VMAT2 Inhibitor			
<b>NBI-1065845¶</b>	Inadequate Response to Treatment in Major Depressive Disorder	AMPA			
<b>luvadaxistat¶</b>	Cognitive Impairment Associated with Schizophrenia	DAAO			
<b>NBI-1117568††</b>	Schizophrenia	M4 Agonist			
<b>NBI-1070770¶</b>	Major Depressive Disorder	NMDA NR2B NAM			
<b>NBI-1117570††</b>	CNS Indications	M1/M4 Agonist			
<b>NBI-1117569††</b>	CNS Indications	M4 Preferring Agonist			
<b>NBI-1117567††,**,  </b>	CNS Indications	M1 Preferring Agonist			
<b>NBI-1065890</b>	CNS Indications	VMAT2 Inhibitor			

EE-CSWS = Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep.  
 SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome.  
 Neurocrine Biosciences has global rights, unless otherwise noted.  
 Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

\* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.  
 § Licensed from Idorsia Ltd.  
 ## Licensed from Xenon Pharmaceuticals, Inc.

† Licensed from Sanofi.  
 ¶ Licensed from Takeda Pharmaceutical Company Limited.  
 †† Licensed from Nxera Pharma (formerly Sosei Heptares).

\*\* Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.  
 || Phase 1 Initiating.